Over 30 million people are at risk of invasive aspergillosis each year due to use of corticosteroids, chemotherapy or other immunosuppressive agents, and over 300,000 patients develop it annually.1
Timely diagnosis and early initiation of therapy strongly influence outcome for patients at risk of invasive fungal infections.
Vircell VirClia® Aspergillus Galactomannan Ag test*
- Fully automated antigen test on the VirClia® instruments
- Ready to use reagents
- Flexibility to run only 1 or multiple samples at a time
- Eliminate delay in results due to batch testing
- Results in 1 hour
- Sample type: serum and Bronchoalveolar Lavage (BAL)
- Shelf life 15 months from manufacturing
References
http://www.life-worldwide.org/fungal-diseases/invasive-aspergillosis
* Please check regulatory status in your country. Not for in vitro diagnostic use in Australia unless first included in the Australian Register of Therapeutic Goods.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
